Cardiovascular Systems (NSDQ:CSII) announced today that it appointed Dr. Jeffery W. Chambers as its chief medical officer.
St. Paul, Minnesota-based Cardiovascular Systems said in a news release that Chambers served as the primary investigator for the Orbit II study — the pivotal trial supporting premarket approval for the use of orbital atherectomy in coronary arteries. He has also served as a consultant in connection with Cardiovascular Systems’ product development, quality assurance, medical affairs and clinical research.
“I am excited to join CSI and I look forward to working with the team to bring innovative and important technologies to underserved patient populations,” Chambers said in the release. “In doing so, together, we will improve the health of people with coronary and peripheral artery disease and fulfill our mission.”
Chambers has been employed at the Metropolitan Heart and Vascular Institute in the Twin Cities since 1995 and, as an entrepreneur, has a number of issued patents, including some associated with devices that are commercially available today, Cardiovascular Systems said. He is a fellow at The American College of Cardiology and is a member of The Society for Cardiovascular Angiography and Interventions.
“CSI is developing an exciting product pipeline that targets some of the fastest-growing segments of interventional cardiology,” Cardiovascular Systems Chairperson, President and CEO Scott Ward said. “Jeff brings contemporary interventional cardiology practice and extensive clinical research experience to CSI as we seek to expand our product offering beyond orbital atherectomy.
“We believe Jeff brings valuable perspective to CSI as we seek to successfully develop and commercialize everolimus drug-coated balloons, intravascular lithotripsy balloons, thrombectomy devices and mechanical circulatory support products.”
